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Introduction 
 
During the past two decades impressive progress has been made in the treatment 
of lysosomal storage diseases (LSDs), a group of genetic disorders caused by 
defects in any aspect of lysosomal biology and characterized by the storage of a 
variety of undegraded molecules in the endosomal/lysosomal compartment 
(Futermann and van Meer, 2004; Jeyakumar et al, 2005). Different therapeutic 
approaches have been developed, including haematopoietic stem cell 
transplantation (HSCT) (Orchard et al, 2007), enzyme replacement therapy (ERT) 
(Brady, 2006), substrate reduction therapy (SRT) (Butters et al, 2005) and enzyme 
enhancement therapy (EET) by pharmacological chaperones (Fan, 2008).  
ERT, a major breakthrough in the treatment of LSDs, was successfully translated 
into the clinical use for some of the most prevalent LSDs, and is currently under 
study for further applications in other disorders. ERT is based on the concept that 
recombinant lysosomal hydrolases, mostly enzyme precursors, manufactured on a 
large scale in eukaryotic cell systems, by interacting with the mannose-6-
phosphate or mannose receptors are internalized by cells and tissues through the 
endocytic pathway and targeted to lysosomes. In the lysosomal compartment they 
are activated and can replace the function of the mutated defective hydrolases. 
Although ERT proved to be highly beneficial in some diseases, or in subsets of 
patients with specific diseases, a number of problems related to its efficacy remain 
unsolved, including bioavailability of recombinant enzymes, the existence of 
“sanctuaries” in which corrective enzyme levels are difficult to achieve, and the 
presence of cellular abnormalities triggered by storage which interfere with ERT 
efficacy ( Futermann and van Meer, 2004). 
These limitations point to the need to identify alternative therapies or to improve 
the efficacy of existing therapy. 
In this thesis I have studied two models of lysosomal disorders, Pompe disease 
(PD) and Fabry disease (FD). 
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PD (glycogenosis type II) is a prototype of LSD in which several of these 
problems, related to ERT efficacy, were encountered both in clinical and in 
laboratory studies.  
PD is a metabolic disorder, with an estimated incidence of 1:40,000 live births, 
caused by defective activity of the lysosomal hydrolase acid α-glucosidase (GAA, 
acid maltase) (Hirschhorn and Reuser, 2001; van der Ploeg and Reuser, 2008). 
GAA deficiency results in generalized intralysosomal glycogen storage, that is 
responsible for extensive damage of muscles, with mechanisms that still remain 
partially understood and probably involve a derangement of autophagy (Raben, 
2007a; Raben, 2007b). As a consequence of the prominent muscular involvement, 
the clinical picture of PD shares common features with that of neuromuscular 
disorders (van der Ploeg and Reuser, 2008). The disease spectrum is extremely 
wide and ranges from the “classic” infantile-onset PD with a rapidly progressive 
course, severe hypertrophic cardiomyopathy, marked hypotonia, hepatomegaly, 
and fatal outcome by one year of age (van den Hout, 2003), to the early or 
childhood-onset “intermediate” phenotypes and the attenuated juvenile and adult-
onset forms, in which cardiac muscle is spared and muscle weakness is the 
primary symptom (van der Ploeg and Reuser, 2008; Kishnani and Howell, 2004; 
Kishnani , 2006).  
Although ERT with recombinant human GAA (rhGAA), available for PD since 
2000 (van den Hout, 2000), showed remarkable success in reverting cardiac 
muscle pathology and extending life expectancy in infantile-onset patients, a 
number of reports suggest that correction of skeletal muscle disease is particularly 
challenging and that not all patients respond equally well to treatment (van der 
Ploeg and Reuser, 2008; van Capelle et al 2008; Thurberg et al, 2006; Willems, 
2008; Schoser , 2008; McVie-Wylie, 2008). These limitations are in part due to 
the insufficient targeting and uptake of the rhGAA used for ERT in muscle, 
resulting in modest increases of tissue enzyme activity (Raben, 2003) and to the 
presence of cellular abnormalities that interfere with the intracellular trafficking of 
the recombinant enzyme (Fukuda , 2006; Cardone, 2008). For these reasons a 
need exists for alternative strategies to the treatment of PD, based on different 
approaches and rationale.  
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FD (OMIM 301500) is an X-linked inherited disease due to alpha-galactosidase A 
(GLA, EC 3.2.1.22) deficiency and characterized by lysosomal storage of 
globotriaosylceramide (Gb3) and related neutral glycosphingolipids (Germain, 
2010).  
Storage of these compounds in vascular endothelia and in multiple organs 
throughout the body results in progressive and potentially life-threatening 
manifestations, including renal failure, cardiomyopathy, premature myocardial 
infarctions, and stroke. FD patients also present with chronic neuronopathic pain, 
gastrointestinal disturbances, and the typical skin angiokeratoma.  
FD is one of the most common lysosomal storage diseases with an estimated 
prevalence of approximately 1 in 100,000 (Meikle, 1999; Germain, 2010), 
although this prevalence may be underestimated (Spada, 2006). Studies in 
selected populations, such as patients with unexplained left ventricular 
hypertrophy (Nakao, 1995; Elliott, 2011) or with renal failure (Nakao, 2003; 
Tanaka, 2005), clearly indicate that in many FD patients non-specific signs and 
symptoms are mistakenly attributed to other diseases. Until the beginning of the 
2000s the management of FD patients was exclusively based on supportive 
therapies. In 2001, enzyme replacement therapy (ERT) with recombinant human 
alpha-galactosidase A (rhGLA) was introduced to treat FD (Eng, 2001; 
Schiffmann , 2001). Two recombinant rhGLA preparations are presently approved 
in Europe for ERT, agalsidase alpha (Replagal, Shire Human Genetic Therapies), 
and agalsidase beta (Fabrazyme, Genzyme Corporation). ERT results in effective 
substrate clearance from vascular endothelia and in clinical improvement or 
stabilization of patients (Metha, 2009). However, substrate removal from other 
cell types and tissues is less efficient and several patients continue to experience 
progressive complications. The published evidence for clinical efficacy of ERT in 
FD has been reviewed in a recent metanalysis (Lidove, 2010). According to this 
study significant clinical benefits of ERT have been demonstrated, mainly in 
patients at an early phase of the disease, with beneficial effects on heart, kidneys, 
pain, and quality of life. However, there are no sufficient data to confirm the long-
term clinical benefits of ERT and to determine the optimal time to start treatment 
in order to prevent irreversible organ damage. Thus, strategies directed towards 
the improvement of ERT efficacy or to the identification of alternative therapeutic 
approaches would be highly desirable. 
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For both these disease models we have explored the potential of  pharmacological 
chaperones therapy (PCT) .  
PCT is based on the concept that loss-of-function diseases are often due to 
missense mutations causing misfolding and degradation of catalytically competent 
enzyme proteins (Fan, 2003; Fan and Ishii, 2007; Hamanaka, 2008). Partial rescue 
of enzyme activity may be obtained by active-site directed competitive inhibitors, 
that can improve folding and stability of mutated proteins with altered 
conformations by acting as folding templates. The use of pharmacological 
chaperones was first proposed in Fabry disease and has been investigated in a 
restricted number of other LSDs, including Gaucher disease, GM1 and GM2 
gangliosidoses. (Parenti, 2009). Two in vitro studies provided the proof of 
principle that PCT may be extended to PD (Okumiya, 2007; Parenti, 2007). In 
both studies two imino sugars, 1-deoxynojirimycin (DNJ) and its alkylated 
derivative N-butyl deoxynojirimycin (NB-DNJ) resulted effective in enhancing 
GAA activity in fibroblasts from PD patient carrying specific mutations of the 
GAA gene. 
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AIM OF THE THESIS 
The general aim of the project of my thesis is to identify novel strategies for the 
treatment of LSDs, in particular Pompe disease, that may translate into improved 
efficacy of the existing therapies for these disorders. The approaches that has been 
evaluated in the project were based on the use of small molecule drugs.  
The first aim of the project was focused on the implementation on PCT in PD. We 
expect that the availability of more specific, non-inhibitory chaperones that  
interact with different non- catalytic protein domains, will expand the fraction of 
GAA gene mutations responsive to PCT and display increased synergy with 
rhGAA. 
The second aim of project is focused  on the  evaluation of therapeutic      
protocols based on the  combination of PCT and  ERT. To this end I have studied  
the synergy between PCT and ERT in PD and in Fabry disease (FD). 
Finally, I am currently studying the mechanism underlying the synergistic effects 
between ERT and PCT. 
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Introduction 
 
The majority of therapeutic approaches for LSDs are aimed at correcting the loss 
of function of the mutated enzyme by increasing the cell and tissue levels of a 
functional protein. 
              An emerging strategy for the treatment of LSDs is PCT, based on the use of 
chaperone molecules that assist the folding of mutated enzymes and improve their 
stability and lysosomal trafficking. After proof-of-concept studies, PCT is now 
being translated into clinical applications for Fabry, Gaucher and Pompe disease. 
This approach, however, can only be applied to patients carrying chaperone 
responsive mutations and limits the use of  chaperone molecules. Other limitations 
of these drugs are scarce  selectivity and potential inhibition of target enzymes 
which could be associated adverse events.  
              Strategies to identify novel chaperone molecules have been already exploited and 
are based on high-throughput screenings with chemical libraries (Colombo, 2008). 
This approach, however is expensive, and requires miniaturization of detection 
methods for large-scale screening of thousands of chemicals. An alternative 
approach is the screening by bioinformatic resources of virtual libraries. In 
principle this approach is cheaper and may help identify classes of compounds to 
be further validated under experimental conditions.  
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OBJECTIVES 
 
The aim of this part of project was the identification of second-generation 
chaperones. 
This part of my project has been conducted in collaboration with  the groups of 
Dr. M. Moracci, Naples and Dr. G. Colombo, Milan that have started a joint 
research program aimed at identifying novel candidate chaperone molecules, 
using a bio-informatic approach. 
After the bionformatic identification of these putative chaperone molecules, I 
tested their biological activity in an vitro cell system for what concerns the 
enhancement of endogenous mutated GAA (in cultured PD fibroblasts and in 
COS7 cells), and in cultured PD fibroblasts and in the PD mouse model to study 
the synergy of PCT and ERT.  
This  bionformatic approach three compounds were identified, that in the thesis 
are referred to as PPC1; PPC2; PPC3. 
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Objective 1 . Enhancement of GAA activity in PD fibroblasts. 
 
We started to test the effects of PPC1 in six cell lines of PD fibroblasts. 
To evaluate the effects of PPC1 on the enzymatic activity of endogenous enzyme, 
we incubated PD fibroblasts in the presence or in the absence of 10mM PPC1.  
The cell lines were incubated for 48 hours with a refresh every 24 hours of 
incubation. At the end of experiment  the cells were harvested and intracellular 
GAA activity was measured. 
 
Results 
We observed that treatment for 48 hr with PPC1  was effective in enhancing GAA 
activity in fibroblasts from patients 2–4 and 6 of 1.2–7 fold increases (Figure 
1.1).  
 
 
OBJECTIVES IN PROGRESS 
 
We are studying for all three PPCs: 
- lysosomal trafficking, maturation and stability by putative chaperones in PD 
fibroblasts. 
-  effects of PPC1 in COS7 cells over-expressing mutated GAA constructs 
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MATERIALS AND METHODS 
 
Cell Lines 
Cells from PD patients are available in the laboratory of the Department of 
Pediatrics, University of Naples, Italy. 
All cell lines were grown at 37°C with 5% CO2, in Dulbecco’s modified Eagle’s 
medium (DMEM, from Invitrogen, NY, USA) and 10% fetal bovine serum (FBS) 
(Sigma-Aldrich, St Louis, MO, USA), supplemented with 100 U/ml penicillin and 
100 mg/ml streptomycin. 
 
GAA enzymatic assay 
GAA activity was assayed by using the fluorogenic substrate 4-
methylumbelliferyl-alpha-Dgalactopyranoside (Sigma-Aldrich).  
GAA enzyme assay. Fibroblasts were harvested by trypsinization and disrupted 
by freezing and thawing (3X). Cell homogenates (30–40 mg of protein) were 
incubated at 37degrees for 60 min with 2mM 4-methylumbelliferyl a-D-
glucopyranoside as substrate in a 0.2 acetate buffer pH 4.0 in an incubation 
mixture of 100 ml. Reactionswere stopped with 1.9 ml glycine carbonate buffer 
pH 10.7 and fluorescence was read on a Turner biosystems fluorometer Modulus 
9200 (360nm excitation, 450nm emission). Protein concentration in cell 
homogenates was measured according to Lowry method. 
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Chapter 2 
 
 
 
Evaluation of therapeutic protocols based on the 
combination of pharmacological chaperones therapy 
(PCT) and enzyme replacement therapy (ERT). 
                                                                                                                                                        17 
 
 
Introduction 
 
It is commonly assumed that PCT should be restricted to the rescue of mutant 
proteins with altered conformations. However, there are reasons to speculate that 
pharmacological chaperones also have an effect on wild type recombinant 
enzymes.  
First, it has been shown that active-site inhibitors induce conformational 
stabilization and protect wild type enzymes from physical agents such as pH and 
thermal inactivation (Pace and McGrath, 1980; Flanagan, 2009). Second, it has 
been demonstrated in vitro, in PD fibroblasts (Cardone, 2008), and in vivo, in 
muscle cells of a PD mouse model (Fukuda, 2006) that a fraction of the rhGAA 
provided as ERT is mistargeted and is thus ineffective. In these systems both 
rhGAA and the cation-independent mannose-6-phosphate receptor (CI-MPR) are 
in part sequestered in vesicles staining positively for LC-3 and in areas of 
autophagic build-up. These results are consistent with the finding that only 50-
70% of the catalytic activity of the infused enzyme can be recovered from tissues 
of the animal model of another LSD, Gaucher disease (Xu, 1996), treated with 
recombinant α-glucocerebrosidase. It is possible that delivery to inappropriate 
cellular compartments exposes recombinant enzymes to degradation and that 
interaction with pharmacological chaperones may enhance, at least in part, 
enzyme stability. A recent paper, showing that pre-incubation of recombinant α-
glucocerebrosidase results in improved uptake and stability (Shen, 2008) in 
fibroblasts from Gaucher disease, apparently supports the hypothesis that PC may 
increase the efficacy of ERT. 
I have tested the effects of the combination of chaperones with ERT in two 
disease models, Pompe disease and Fabry disease. 
In principle, treatment protocols based on the combination of different therapies 
and tailored to single patients (personal medicine) may be particularly useful in 
reaching therapeutic enzymatic correction in tissues responding poorly to therapy. 
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OBJECTIVES 
 
 The second aim of project is focused  on the  evaluation of therapeutic      
protocols based on the  combination between PCT and ERT. I have studied the 
synergy between PCT and ERT in PD and FD. 
 
OBJECTIVE 1. Effect of NB-DNJ on GAA activity in fibroblasts 
treated with rhGAA. 
We incubated PD fibroblasts with 50 μM rhGAA in the presence or in the absence 
of 20 μM NB-DNJ. The chaperone concentration of 20 μM has been previously 
shown to be effective in rescuing mutated GAA (Parenti, 2007). This 
concentration is the a range that can be achieved in Gaucher patients treated with 
this drug as a substrate reducing agent for its inhibitory effect on ceramide 
glucosyltransferase (Cox, 2000). After 24 hours the cells were harvested and the 
correction of enzyme activity was analyzed. 
In all PD cell lines co-incubation with rhGAA and NB-DNJ resulted in more 
efficient correction of enzyme activity (Figure 2.1a) as compared to the activity 
obtained in cells incubated with the recombinant enzyme.  
This effect was not due to enhancement of the endogenous GAA residual activity, 
as improved correction was seen in all PD cells tested, including cells from 
patients carrying mutations that are non-responsive to pharmacological 
chaperones (PD2, PD4 and PD5). In addition, the increase of GAA activity in 
chaperone-responsive cells, after co-administration of rhGAA and NB-DNJ, was 
much higher than that observed after incubation with the chaperone alone 
(Parenti, 2007;  Okumiya T., 2007). Also, studies with the AlexaFluor546-
labelled rhGAA in PD1 and PD2 fibroblasts showed increased fluorescence 
intensity in cells incubated with NB-DNJ (Figure 2.1b). Since by this approach 
only the exogenous rhGAA can be detected, these results confirm that the effect 
of NB-DNJ on enzyme activity was not due to the enhancement of the 
endogenous mutated GAA. 
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Pre-incubation of rhGAA with the chaperone did not result in enhanced correction 
GAA. 
Objective 2. Effect of NB-DNJ on rhGAA delivery to lysosomes 
and maturation 
To investigate the mechanisms leading to the enhanced GAA correction, we will 
study rhGAA trafficking in two of the PD cell lines (PD1 and PD2). We have 
previously demonstrated that these PD cell lines show reduced availability of CI-
MPR at the plasma membrane and impaired rhGAA uptake. In addition, PD 
fibroblasts showed inefficient delivery of the internalized enzyme to lysosomes 
(Cardone, 2008).  
We have labelled rhGAA with the fluorochrome AlexaFluor546 and we have 
studied its intracellular distribution in PD fibroblasts in the absence or in the 
presence of 20 μM NB-DNJ. 
To perform colocalization studies, PD cells were incubated with AlexaFluor546-
rhGAA for 4-8 hours; then they were fixed, stained with an antiserum against the 
lysosomal marker LAMP2, and analyzed by confocal microscopy and finally  we 
will perform an analysis of co-localization  coefficients of rhGAA-LAMP2. 
To validate these data I performed western blot analysis of the GAA polypeptides 
in  PD1 and PD2 cell homogenates after a time course of incubation with rhGAA, 
in the presence and  absence of chaperone, consistent with the time required for 
enzyme maturation.(Moreland RJ, 2005). 
 
Results 
PD cells internalized less fluorochrome-labelled rhGAA, as compared to controls 
(Figure 2.2 a) and showed abundant LAMP2 signal, delimitating enlarged 
vesicles, a pattern consistent with the staining of a membrane-associated 
lysosomal protein and with the presence of lysosomal storage and expansion. In 
both cell lines incubation with NB-DNJ improved lysosomal targeting, with 
increased coefficients of rhGAA-LAMP2 co-localization (Figure 2.2 b). 
Consistent with these data were the results of a western blot analysis of the GAA 
polypeptides. In both PD1 and PD2 cell homogenates GAA maturation into the 
70-76 kDa molecular forms was enhanced in the presence of the chaperone 
(Figure 2.3 a), indicating improved delivery to the late endosomal/lysosomal 
compartment. 
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The improved maturation was also confirmed by studying the time-course of 
GAA correction in PD cells incubated with rhGAA (Figure 2.3 b). We found that 
substantial enhancement of GAA correction by NB-DNJ is seen only after 8-18 
hours of incubation, a time consistent with the time required for enzyme 
maturation, and that the gap in enzyme correction between cells incubated with 
and without the chaperone becomes progressively wider, as increasing amounts of 
the active molecular forms are generated in chaperone-treated cells. 
 
Objective 3. Effects of NB-DNJ on the rhGAA stability 
It is possible that, as a result of the abnormal trafficking and inappropriate 
compartimentalization of rhGAA, its stability is affected. 
To study GAA stability PD fibroblasts were incubated with 50 µM rhGAA for 24 
hours and then we will chased the cells for variable times, up to 30 hours, to 
analyze the decline of intracellular enzyme activity and of GAA polypeptides. 
 
Results 
We observed that in PD1 and PD2 cells rhGAA activity decreases within a few 
hours after removing rhGAA from the medium. When PD cells were incubated 
with rhGAA in the presence of 20 µM NB-DNJ, enzyme stability increased in 
PD1 and PD2 (Figure 2.4 a). These data were also confirmed by the western-blot 
analysis of GAA, showing prolonged persistence of the mature 76 kDa GAA 
polypeptides in the presence PD fibroblasts incubated with NB-DNJ  
(Figure 2.4 b). 
 
 
Objective 4. Effect of NB-DNJ on the correction of GAA activity 
in vivo 
A major therapeutic goal in PD is to achieve corrective enzymatic levels in 
skeletal muscle, where ERT effects are variable. 
For this reason we  studied the combination of ERT with rhGAA and NB-DNJ in 
a KO mouse model of PD. Mice were treated with oral NB-DNJ at a dose of 4.3 
mg/kg for two days. On the second day they  received a single tail-vein injection 
of rhGAA at a dose of 40 mg/kg, comparable to that used in PD patients. Organs 
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and tissues from mice were harvested 48 hrs after the injection, GAA activity was 
assayed, and the results was compared to those obtained in animals treated with 
rhGAA alone. 
 
Results 
We observed an improved enzyme correction in gastrocnemium (1.57-fold 
increase as compared to animals treated with rhGAA alone) and in diaphragm (2-
fold increase). Activities measured in liver were extremely high, consistent with 
the reports showing preferential uptake of GAA by this organ (Raben et al, 2003), 
and showed minimal increase (1.03-fold) in animal treated with the combination 
of ERT and NB-DNJ. (Figure 2.5). 
 
 
                  Objective 5. Synergy of PPC1 with ERT in PD fibroblasts. 
The search for novel chaperones is important also for the improvement of recent 
protocols of combination between ERT and PCT. 
To validate the hypothesis of a synergy between PPC1 and ERT, we incubated PD 
fibroblasts with 50 µM rhGAA in the presence or in the absence of 10mM PPC1. 
We pre-incubated our cell lines for 48 hours with PPC1 with a refresh every 24 
hours of incubation. 
Then  the cells were incubated with Myozyme and harvested after 24 hours. 
Finally the correction of enzyme activity was analyzed. 
 
Results 
In all PD cell lines co-incubation with rhGAA and PPC1 resulted in more efficient 
correction of enzyme activity  as compared to the activity obtained in cells 
incubated with the recombinant enzyme alone. 
The correction of GAA activity in the cells incubated with the recombinant 
enzyme alone was variable among the different cell lines with specific activities 
ranging from 10 to 40 nmoles 4-methylumbelliferone/mg protein/hour).  
When the cells where co-incubated with PPC1 and rhGAA we observed an 
improved correction of intracellular activity  ranging from 3.2 to 14.4-fold, 
compared to cells incubated with rhGAA alone, superior to that obtained with 
NB-DNJ  (Figure 2.6).  
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Objective 6. Effect of PPC1 on rhGAA subcellular distribution 
and processing of in PD fibroblasts. 
Lysosomal targeting is important since rhGAA is provided as the 110 kDa GAA 
precursor that, upon reaching the late endosomal/lysosomal compartment, is 
proteolytically processed, within 8-16 hrs  into the active polypeptides of 76 and 
70 kDa, through an intermediate molecular form of 95 kDa (Moreland RJ, 2005). 
Improving the targeting of rhGAA to lysosomes is therefore crucial for correction 
of the enzymatic defect in PD cells. 
We have labelled rhGAA with the fluorochrome AlexaFluor546 and we have 
studied its intracellular distribution in PD fibroblasts in the absence or in the 
presence of 10 mM PPC1. 
To perform colocalization studies, PD cells were incubated with AlexaFluor546-
rhGAA for 4-8 hours; then they were fixed, stained with an antiserum against the 
lysosomal marker LAMP2, and analyzed by confocal microscopy and co-
localization  coefficients of rhGAA-LAMP2 were analyzed. 
The processing of rhGAA was studied by western blot analysis of the GAA 
polypeptides in  PD3  cell homogenates in the presence and  absence of putative 
chaperone. 
 
Results 
In both cell lines incubation with PPC1 improved lysosomal targeting, with 
increased co-localization of rhGAA-LAMP2 (Figure 2.7a ). 
Consistent with these data were the results of a western blot analysis of the GAA 
polypeptides, showing an increased amount of the mature 76 kDa GAA 
polypeptides in PD fibroblasts incubated with PPC1 (Figure 2.7b ). 
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Objective 7. Effects of  DGJ in FD 
A preliminary experiment, reported in (Porto, 2009) suggested that the synergy 
between ERT and a chaperone molecule was not limited to PD, but could be 
extended to FD. 
Here we provide formal demonstration in six FD fibroblast cell lines that the 
combination of ERT and PCT results in improved correction of GLA activity, and 
facilitated lysosomal trafficking and stability of the recombinant enzyme. Our 
results imply that this combination therapy may represent a way to improve the 
efficacy of ERT in any lysosomal storage disease treatable by this approach. 
FD fibroblasts were incubated with rhGLA, with DGJ, or with both. After 24        
hours the cells were harvested and the intracellular activity of GLA was measured.  
 
Results 
None of the cell lines showed significant increases in baseline activity when 
incubated with the chaperone alone, indicating that the GLA gene mutations of 
these patients were non-responsive to PCT. The correction of GLA activity in the 
cells incubated with the recombinant enzyme alone was variable among the 
different cells lines and ranged from 19.9 to 80.6 nmoles 4-
methylumbelliferone/mg protein/hour).  
When the cells where co-incubated with DGJ and rhGLA we observed a highly 
improved correction of intracellular activity. Increases in GLA activity ranged 
from 4.8 to 16.9-fold, compared to cells incubated with rhGLA alone (Figure 
2.8a). The effect of the combination of ERT and PCT in FD fibroblasts was much 
higher than that observed in our previous study on the synergy of ERT and 
chaperones in PD fibroblasts (Porto, 2009). The enhancing effect of DGJ was not 
directed to the endogenous mutated GLA. First, the cell lines studied were from 
patients with mutations non-responsive to the chaperone.  
Second, we observed an increase in the amount of fluorochrome-labelled rhGLA 
in the presence of DGJ, compared to cells incubated with fluorescent rhGLA 
alone (Figure 2.8b).   
By this approach only the fluorescent exogenous enzyme is detectable and 
variations in the intensity of fluorescence reflect only the effects on the 
recombinant enzyme. Finally, the enhancing effect of DGJ on was abolished in 
the presence of mannose-6-phosphate (Figure 2.8c).  
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Objective 8. Effect of DGJ on the rhGLA stability and  lysosomal 
trafficking in cultured fibroblasts from FD patients. 
To study if the amount of recombinant enzyme and its intracellular distribution 
was influenced by DGJ I performed western blot analysis of fibroblasts from all 
patients (Figure 2.9a).  and confocal immunofluorescence studies with 
fluorochrome-labeled rhGLA. 
 
Results 
Co-administration of DGJ and rhGLA resulted in a substantial increase in the 
amount of intracellular enzyme compared with cells treated with rhGLA alone, 
suggesting improved intracellular stability of the enzyme. The large increase in 
GLA protein in cells treated with rhGLA and DGJ, compared to the cells treated 
with rhGLA alone, was consistent with the high levels of GLA enzyme activity 
obtained with the combination therapy (Figure 2.9a).  
Confocal immunofluorescence studies showed an improved co-localization of the 
fluorochrome-labeled enzyme with the lysosomal marker LAMP2, indicating 
facilitated delivery of the recombinant enzyme to the lysosomal compartment 
(Figure 2.9b).  
 
Objective 9. Studies on the specificity of the effect of DGJ on 
rhGLA.  
To test whether the effect of chaperones on recombinant enzymes is specific, we 
incubated one of the FD cell lines with rhGLA in the presence of NB-DNJ, a 
known chaperone for GAA, the enzyme deficient in PD. Conversely, we 
incubated PD fibroblasts with rhGAA in the presence of DGJ.  
 
Results 
In both cases the inappropriate nonspecific chaperone had no enhancing effect on 
each of the recombinant enzymes (Figure 2.10). This indicates that for the 
enhancing effect of chaperones on recombinant enzyme specific molecular 
interactions between the drug and the catalytic sites of each enzyme are required. 
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Objective 10. DGJ reduces lyso-Gb3 levels in FD cultured 
fibroblasts  
                       It has been reported that, in addition to Gb3, other secondary substrates 
accumulate in FD. One of them is lyso-Gb3, a deacylated Gb3, that has been 
shown to contribute to FD pathophysiology by inducing proliferation of smooth 
muscle cells and promoting cellular storage. Due to the high structural similarity 
to Gb3, lyso-Gb3 is a potent inhibitor of GLA [Aerts et al, 2006] and, in principle, 
may limit the efficacy of ERT in FD patients. We tested the effects of the 
combination of rhGLA and DGJ on intracellular lyso-Gb3 levels in four of  the 
FD fibroblast cell lines (patients 1, 3, 4 and 5). All cell lines showed detectable 
levels of lyso-Gb3 under baseline conditions. Incubation of these cells for 24 
hours with rhGLA reduced substantially (by 36.8%) lyso-Gb3 levels (Figure 
2.11).  
 
Results 
Co-administration of DGJ and rhGLA resulted in improved clearance of the 
substrate (with average decrease of 51.0% with respect to untreated cells), 
indicating better efficacy of the combination regimen. Interestingly, DGJ by itself 
had an effect on lyso-Gb3 intracellular levels, with an average decrease of 18.9%. 
This effect on a potential inhibitor of GLA may contribute to the improved 
correction of GLA activity observed in FD fibroblasts and explain the massive 
rhGLA enhancement in the presence of DGJ. The reduction of lyso-Gb3 by DGJ 
alone cannot be ascribed to a chaperone effect of the drug on the endogenous 
mutated GLA, as all cell studied were unresponsive to the chaperone (see above 
and Figure 1A). Thus, these results suggest that DGJ interferes directly on lyso-
Gb3 synthesis. 
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CONCLUSIONS 
 
The combination of ERT and PCT results in improved correction of GLA activity, 
and facilitated lysosomal trafficking and stability of the recombinant enzyme. Our 
results imply that this combination therapy may represent a way to improve the 
efficacy of ERT in any lysosomal storage disease treatable by this approach. 
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MATERIALS AND METHODS 
 
Fibroblast cultures  
Fibroblasts from PD and FD patients were derived from skin biopsies after 
obtaining the informed consent of patients. Normal age-matched control 
fibroblasts were available in the laboratory of the Department of Pediatrics, 
Federico II University of Naples. All cell lines were grown at 37°C with 5% CO2 
in Dulbecco’s modified Eagle’s medium (Invitrogen, Grand Island, NY) and 10% 
foetal bovine serum (Sigma-Aldrich, St Louis, MO), supplemented with 100 U/ml 
penicillin and 100 mg/ml streptomycin.  
 
Reagents  
The recombinant enzymes alglucosidase-alfa (Myozyme) and agalsidase-beta 
(Fabrazyme) were from Genzyme (Naarden, the Netherlands). As source of 
enzyme we used the residual amounts of the reconstituted recombinant enzyme 
prepared for the treatment of PD patients at Department of Cardiology and  FD 
patients at the Department of Nephrology, Federico II University, Naples. The 
chaperones DGJ and NB-DNJ were purchased from Sigma-Aldrich.  
The anti GLA primary antibody used for immunofluorescence and western blot 
analysis was purchased from Abnova, Heidelberg, Germany; the anti-beta-actin 
mouse monoclonal antibody was from Sigma-Aldrich; the anti-human LAMP2 
mouse monoclonal antibody was from Santa Cruz Biotechnology, Santa Cruz, 
CA. Anti-rabbit and anti-mouse econdary antibodies conjugated to Alexa Fluor 
488 or 596 were from Molecular Probes, Eugene, OR; HRP-conjugated anti-rabbit 
or anti-mouse IgG were from Amersham, Freiburg, Germany. Labeling of rhGLA 
was performed using the Alexa Fluor 546 labeling kit (Molecular Probes) 
according to the manufacturer instructions.  
 
Uptake of rhGAA and correction of GAA activity 
To study rhGAA uptake and correction of GAA activity PD fibroblasts were 
incubated with  50 µM of rhGAA for 24 hours. The cells were then harvested and 
cell pellets were washed twice with PBS, resuspended in water and disrupted by 
five cycles of freeze-thawing. GAA activity was assayed as already described 
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(Parenti, 2007). Protein concentrations were determined in total homogenates by 
the Bradford assay (Bio-Rad, Hercules, CA). 
 
 
Incubation of FD fibroblasts with rhGLA and GLA assay  
To study the rhGLA uptake and correction of GLA activity in FD fibroblasts, the 
cells were incubated with 5 nmol/l rhGLA for 24 hours, in the absence or in the 
presence of 20 µmol/l DGJ. Untreated cells or cells incubated with DGJ alone 
were used for comparison. After the incubation the cells were harvested by 
trypsinization and disrupted by 5 cycles of freezing and thawing. To inhibit the 
uptake of rhGLA the cells were incubated with the recombinant enzyme in the 
presence of 5 mmol mannose-6-phosphate (Sigma Aldrich).  
 
GLA activity was assayed by using the fluorogenic substrate 4-
methylumbelliferyl-alpha-Dgalactopyranoside (Sigma-Aldrich).  
Twenty-five micrograms of protein were incubated with 3 mmol/l concentrations 
of substrate and 0.1 M N-acetyl-D-galactosamine in 0.2 mmol/l acetate buffer, pH 
4.5, for 60 minutes in incubation mixtures of 300 µl. The reaction was stopped by 
adding 700 µl of glycine-carbonate buffer, pH 10.7. Fluorescence was read at 365 
nm (excitation) and 450 nm (emission) on a Turner Biosystems Modulus 
fluorometer.  
Protein concentration in cell homogenates was measured by the Bradford assay 
(Biorad, Hercules, CA).  
 
 
 
Western blot analysis  
To study GAA and GLA immunoreactive material, fibroblast extracts were 
subjected to western blot analysis. The cells were harvested, washed in phosphate-
buffered saline, resuspended in water, and disrupted by five cycles of freeze-
thawing. Equal amounts (20 µg protein) of fibroblast extracts were subjected to 
sodium dodecyl sulfate polyacrylamide gel electrophoresis and proteins were 
transferred to PVD membrane (Millipore, Billerica, MA).  
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An anti-human GLA antiserum and  anti-human GAA antiserum were used as 
primary antibody to detect GAA and GLA polypeptides; to detect ß-actin, a 
monoclonal mouse antibody was used. Immunoreactive proteins were detected by 
chemiluminescence (ECL, Amersham, Freiburg, Germany).  
 
Immunofluorescence analysis and confocal microscopy  
To study the distribution of GAA and GLA and their colocalization with LAMP2. 
We incubated  PD; FD  and control fibroblasts with labelled enzymes. Then the 
cells  that were grown on coverslips, were fixed using methanol, permeabilized 
using 0.1% saponin and blocked with 0.01% saponin, 1% foetal bovine serum 
diluted in phosphate-buffered saline for 1 hour. The cells were incubated with the 
primary antibodies, with secondary antibodies in blocking solution and then 
mounted with vectashield mounting medium (Vector Laboratories, Burlingame, 
CA).  
Samples were examined with a Zeiss LSM 5 10 laser scanning confocal 
microscope.  
 
Analysis of lyso-Gb3 in fibrobalst extracts.  
 The quantitative analysis of lyso-GB3 in FD fibroblasts was performed according 
to published methods, with slight modifications [Boscaro et al, 2002] using liquid 
chromatrography coupled with electrospray ionization-tandem mass spectrometry 
(LCESI-MS/MS). Retention time of lyso-Gb3 was o.65 minutes in a 2.80 minute 
run. The detection of the analytes of interest was achieved using a triple 
quadrupole instrument operating in the multiple reaction monitoring mode. The 
statistical significance of the effects of DGJ and rhGLA on Lyso-Gb3 levels in 
fibroblasts was evaluated by a chi-square test. 
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                 Chapter 3 
 
 
 
Understanding the mechanisms underlying the synergistic 
effect of pharmacological chaperones therapy (PCT) and 
enzyme replacement therapy (ERT). 
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Introduction 
 
The synergy between ERT and PCT is innovative and may translate into improved 
therapies for patients with PD, FD and, in principle, with any other LSD for which 
an ERT and a chaperone are available.  In this respect it is worth mentioning that 
phase 2/3 clinical trials in are in progress on the combination of ERT and PCT for 
PD and FD.  
However, the mechanism underlying this synergy are not clear, yet, and need to 
be fully understood.  
In principle, by interacting with w.t enzymes, chaperones may induce 
conformational changes and enhance uptake, lysosomal trafficking and stability of 
the enzyme. 
We are presently investigating in detail each of these three aspects, separately, and 
we are planning to evaluate whether the effect of the chaperones is directed 
toward one of them or results from the combination of different effects. 
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OBJECTIVES 
To understand the mechanisms involved in the synergy between ERT and PCT, 
we are studying the effect of the chaperone molecule NB-DNJ on the intracellular 
trafficking of rhGAA in PD fibroblasts.  
This part of the project is still in progress and the results are preliminary.  
 
Objective 1: Studies on the  binding of labelled rhGAA with plasma 
membrane 
                        The binding of fluorochrome-labelled rhGAA with plasma 
membrane of 
 fibroblasts will be studied in the absence and in the presence of NB-DNJ 
 (20mcrM). rh-GAA will be labeled with the fluorochrome AlexaFluor546, 
according to the manufacturer instructions. The cells will be incubated with 
 the labelled rhGAA at 4-16°C to prevent rhGAA internalization, for 2-4 hrs. 
 The cells will then be fixed and analyzed by confocal immunofluorescence. 
 
Objective 2: Studies on the kinetics of rhGAA uptake 
The kinetics of rhGAA uptake will be studied in fibroblasts incubated with 
different concentrations of mannose-6-phosphate (1, 2, 5, 10 mM). GAA   
activity will be measured in fibroblast homogenates to evaluate the amounts 
of rhGAA internalized by cells. 
 
 Objective 3: Studies on the rhGAA trafficking  
The cells will be incubated with the labelled rhGAA. The co-localization of the 
fluorescent recombinant enzyme with the CI-MPR and markers of different 
cellular compartments (EEA1, LAMP2, GM130, LC3) will be evaluated at 15, 30, 
and 60 minutes by confocal immunofluorescence as described previously 
(Cardone , 2008).  
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Preliminary results 
PD fibroblasts and control fibroblasts were cultured for three days in presence and 
in absence of DGJ and NB-DNJ, respectively, and then incubated with   
fluorochrome-labeled rhGAA . The cells were kept at low temperature (0 - 4 
degrees) to synchronize rhGAA trafficking. At this temperature the binding of 
rhGAA with the CI-MPR can take place, but the internalization of the 
recombinant enzyme through the endocytic pathway is blocked. The cells are then 
warmed at 37 degrees and the intracellular trafficking was studied at variable 
times. 
I observed that less enzyme is internalized in mutant cells compared to controls 
and that at the earlier time-point the most part of the enzyme is present in the early 
endocytic compartment (co-localizes with the endocytic marker EEA1) in PD 
cells. (Figure 3.1), after 60 minutes at 37 degrees most of rhGAA colocalizes 
with LAMP1. 
These observations suggest that the trafficking of the recombinant enzyme to 
lysosomes is retarded in PD, compared to the control. 
In the presence of the chaperone the intracellular amount of the enzyme increased 
and the lysosomal trafficking was accelerated as indicated by the improved 
colocalization of rhGAA with LAMP1 at 15’ after the shift to 37 degrees.  
(Figure 3.1) 
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MATERIALS AND METHODS 
 
To study the intracellular distribution of  the enzyme we have labelled rhGAA 
with the fluorochrome AlexaFluor546. Then we performed colocalization studies, 
with EEA1 and LAMP1as indicated in chapter 2. 
 PD cells were incubated with the labeled-enzyme at low temperature (0 o 4 
degrees) to synchronize rhGAA trafficking.  
The cells are then warmed at 37 degrees and the intracellular trafficking is studied 
at variable times. 
After 15 minutes and 60 minutes from the shift at 37 degrees the cells were fixed 
and stained with an antiserum against  endosomal  and lysosomal markers, EEA1 
and LAMP1. 
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